OPKO HEALTH INC. Inactive Instrument
Opko Health Inc. Share Price Nyse
Equities
US68375N1037
Healthcare Facilities & Services
|
End-of-day quote
Other stock markets
|
||
| - USD | - |
|
| 05-07 | Earnings Flash (OPK) OPKO HEALTH Posts Q1 Revenue $173.7M, vs. Street Est of $183M | MT |
| 05-07 | Transcript : OPKO Health, Inc., Q1 2024 Earnings Call, May 07, 2024 |
| Sales 2024 * | 715M 56.31B | Sales 2025 * | 754M 59.37B | Capitalization | 920M 72.44B |
|---|---|---|---|---|---|
| Net income 2024 * | -265M -20.87B | Net income 2025 * | -195M -15.35B | EV / Sales 2024 * | 1.29 x |
| Net cash position 2024 * | - 0 | Net cash position 2025 * | - 0 | EV / Sales 2025 * | 1.22 x |
| P/E ratio 2024 * |
-3.54
x | P/E ratio 2025 * |
-4.89
x | Employees | - |
| Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 45.64% |
More Fundamentals
* Assessed data
More news
Latest transcript on Opko Health Inc.
More recommendations
More news
| Managers | Title | Age | Since |
|---|---|---|---|
Phillip Frost
CEO | Chief Executive Officer | 87 | 26/03/07 |
Adam Logal
DFI | Director of Finance/CFO | 46 | 28/02/07 |
Elias Zerhouni
PSD | President | 72 | 08/05/22 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Phillip Frost
CEO | Chief Executive Officer | 87 | 26/03/07 |
Roger Medel
BRD | Director/Board Member | 77 | 17/12/20 |
| Director/Board Member | 68 | 31/12/07 |
OPKO Health, Inc. is a multinational biopharmaceutical and diagnostics company. The Company's diagnostics segment consists of the clinical laboratory operations of BioReference Health, LLC (BioReference), its point-of-care operations. Its pharmaceutical segment consists of the pharmaceutical operations in Chile, Mexico, Ireland, Israel, Spain, Ecuador, France, the United States, and its pharmaceutical research and development operations. Through BioReference, it operates specialized laboratory divisions, such as GenPath (Urology), GenPath (Oncology), and GenPath (Women's Health). It has two commercial stage pharmaceutical products and several pharmaceutical compounds and technologies in various stages of research and development for a range of indications and conditions, including Rayaldee, Rayaldee, Oxyntomodulin, Biologics, NGENLA Somatrogon, and Factor VIIa-CTP. It develops and manufactures specialty active pharmaceutical ingredients (APIs) through FineTech Pharmaceutical, Ltd.
Calendar
31/07/2024
- Q2 2024 Earnings Release (Projected)
Related indices
| 1st Jan change | Capi. | |
|---|---|---|
| -16.99% | 8.55B | |
| +65.23% | 4.24B | |
| -1.63% | 2.54B | |
| -10.68% | 2.44B | |
| -41.76% | 2.35B | |
| -8.53% | 1.89B | |
| -19.29% | 1.55B | |
| -39.61% | 1.23B | |
| +9.54% | 1.13B |
